Search results
Results from the WOW.Com Content Network
A high-dose vaccine (Fluzone High-Dose) four times the strength of standard flu vaccine was approved by the FDA in 2009. [22] [23] [24] This vaccine is intended for people 65 and over, who typically have weakened immune response due to normal aging. The vaccine produces a greater immune response than standard vaccine.
The vaccine is based on the A/H5N8/Astrakhan/3212/2020 clade 2.3.4.4b strain of influenza. [14] If needed, the H5 vaccine could be used while a pandemic-specific vaccine is developed and produced. [15] In June 2024, the European Commission signed a four-year contract with CSL Seqirus to secure 665,000 pre-pandemic vaccines with a provision for ...
The following is a list of WHO recommended strains for the Northern Hemisphere influenza season. Starting in the 2012–2013 season, the recommendation shifted to include the composition of a quadrivalent influenza vaccine (QIV) that contains both influenza B lineages, alongside a trivalent influenza vaccine (TIV) containing one influenza B lineage.
In a 2010 survey of United States healthcare workers, 63.5% reported that they received the flu vaccine during the 2010–11 season, an increase from 61.9% reported the previous season. US Health professionals with direct patient contact had higher vaccination uptake, such as physicians and dentists (84.2%) and nurse practitioners (82.6%).
Sanofi will also make sure it is prepared to manufacture an egg-based influenza vaccine, such as a vaccine for H5 influenza, which is a strain of bird flu, if needed.
US FDA approves AstraZeneca's self-administered nasal spray flu vaccine. ... and 4,900 to 51,000 deaths annually between 2010 and 2023. ... Sanofi and CSL, among others, also make flu vaccines.
Flu shots are by far the most common flu vaccine available, although there is also a nasal spray. You can get the spray if you’re healthy, between the ages of 2 to 49, and if you aren’t pregnant.
CSL was founded in 1916 as Commonwealth Serum Laboratories, an Australian government body focused on vaccine manufacture. [4] Under the first director, William Penfold, [5] CSL commenced operation in the vacant Walter and Eliza Hall Institute building at the Royal Melbourne Hospital in 1918 before moving to its purpose-built Parkville premises in the following year.